Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11), FiscalAI reports. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The firm had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $9.74 million. During the same period last year, the firm earned ($0.92) EPS. The business’s quarterly revenue was down 47.8% on a year-over-year basis.
Intellia Therapeutics Stock Up 2.3%
Shares of NTLA traded up $0.25 during midday trading on Friday, hitting $11.35. The company had a trading volume of 4,402,763 shares, compared to its average volume of 5,128,128. The company’s 50 day moving average price is $12.13 and its 200 day moving average price is $13.06. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -3.38 and a beta of 1.83. Intellia Therapeutics has a 52 week low of $7.95 and a 52 week high of $18.48.
Insider Activity at Intellia Therapeutics
In other news, CEO John M. Leonard sold 9,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $11.99, for a total transaction of $107,910.00. Following the transaction, the chief executive officer owned 1,138,064 shares of the company’s stock, valued at approximately $13,645,387.36. This trade represents a 0.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.50% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on NTLA shares. Evercore raised shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price objective for the company in a research report on Friday, August 7th. Barclays initiated coverage on Intellia Therapeutics in a research report on Tuesday, October 6th. They set an “underweight” rating and a $8.00 target price on the stock. Wolfe Research downgraded Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price target for the company. in a report on Wednesday, July 15th. Wall Street Zen downgraded Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have given a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $20.57.
Get Our Latest Stock Analysis on Intellia Therapeutics
About Intellia Therapeutics
Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.
Intellia’s pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.
Read More
- Five stocks we like better than Intellia Therapeutics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
